---
title: 'Morning Brief — Wednesday, November 18, 2026'
type: 'episode'
url: 'https://doc.social/episodes/morning-brief-2026-11-18'
show: 'doc social Morning Brief'
show_url: 'https://doc.social/podcasts/morning-brief'
published: '2026-11-18'
audio: 'https://media.doc.social/podcasts/morning-brief/2026-11-18.mp3'
---

# Morning Brief — Wednesday, November 18, 2026

CMS proposed rule CMS-6098-P, Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH), 545 pages, on public inspection Nov 17 (filed Nov 16), publishes Nov 19: all providers billing MA must enroll in Original Medicare (including out-of-network), all enrollment changes reported within 30 days (vs 30/90 today), broader denial/revocation grounds, DMEPOS unsolicited-contact prohibition and…

## Summary

4 stories this morning, for surgeons and the people who support them.

- **CMS proposed rule CMS-6098-P, Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH), 545 pages, on public inspection Nov 17 (filed Nov 16), publishes Nov 19: all providers billing MA must enroll in Original Medicare (including out-of-network), all enrollment changes reported within 30 days (vs 30/90 today), broader denial/revocation grounds, DMEPOS unsolicited-contact prohibition and marketer transparency; 60-day comment period** — Federal Register public inspection document 2026-23461 (proposed rule, RIN 0938-AV97, docket CMS-2026-0826), scheduled for publication 2026-11-19, comments due 60 days after publication. Provisions verified in rule text: requirement that all providers that bill MA be enrolled in Original Medicare, expanded to out-of-network MA providers, largely mirroring the November 2016 final rule replaced by the April 2018 preclusion list; 'well over 100,000 in-network providers remain unenrolled'; 'all changes of information ... be reported within 30 days' (currently 30 days for ownership, practice location, final adverse actions and 90 for most others); expanded grounds for enrollment denial and revocation; DMEPOS clarification making explicit the prohibition on unsolicited beneficiary contact by suppliers and their agents, transparency on domestic and foreign marketers, surety bond changes; rule cites orthotic-brace telemarketing fraud cases. Also covers Medicaid/CHIP oversight, MA RADV, Marketplace brokers. Not previously covered. [Source](https://public-inspection.federalregister.gov/2026-23461.pdf)

- **Medtronic announces FDA 510(k) clearance of the Hugo RAS system for general surgery: all upper abdominal general surgical procedures plus inguinal hernia and appendectomy (~3.5M US procedures/yr); first US clearance was urology (announced Dec 3, 2025)** — Medtronic release Nov 17, 2026: clearance covers all upper abdominal general surgical procedures including cholecystectomy, Roux-en-Y gastric bypass, ventral hernia and small bowel resection, plus inguinal hernia and appendectomy; about 3.5 million US surgeries annually, more than half of soft-tissue procedures. Hugo procedure growth >2x robotic market, on track to surpass 50,000 procedures by end of Medtronic fiscal year; general surgery is highest-growth OUS specialty. Second source: MedTech Dive (https://www.medtechdive.com/news/medtronics-hugo-robot-gets-expanded-fda-clearance-in-general-surgery/874904/), which also notes J&J Ottava authorization in July (J&J/Business Wire July 17, 2026, De Novo, upper abdominal) and Stryker's October deal to distribute CMR Versius in the US (covered 2026-10-13). Intuitive installed base 12,094 at Sept 30, 2026 (Q3 EX-99.1, covered 2026-10-21). Hugo previously mentioned only as context 2026-09-02 (Cornerstone/Sentire) and 2026-09-29 (FDA RAS guidance); this clearance is new. [Source](https://www.prnewswire.com/news-releases/medtronic-announces-fda-clearance-of-general-surgery-procedures-for-the-hugo-robotic-assisted-surgery-ras-system-302941366.html)

- **Vy Spine announces FDA clearance of VySion-P SI Fusion (intra-articular, PEEK/PEKK, must be paired with a transfixing VyStop screw as a hybrid construct) and VyStop SI Screw systems, including the sacropelvic-fixation adjunct indication** — Vy Spine release (Bountiful, UT, Nov 17, 2026), also reported by ORTHOWORLD (https://www.orthoworld.com/vy-spine-earns-fda-clearance-for-vysion-p-si-fusion-system/). Indications: SI fusion for degenerative sacroiliitis and SI joint disruption, and to augment SI stabilization in skeletally mature patients undergoing sacropelvic fixation as part of lumbar/thoracolumbar fusion; VyStop also for SI joint fractures. VySion-P offered in PEEK Optima LT1, HA-enhanced PEEK, NanoVy Ti-coated PEEK and OsteoVy PEKK (Oxford Performance Materials OXPEKK); company claims first polymeric device of its kind cleared for SI fusion and that OXPEKK is bacteriostatic and suited to metal hypersensitivity (attributed, not settled). No K number, clinical data or launch timing in the release. Context: SI-BONE iFuse Bedrock Granite and Xenix Riva Anchor (covered 2026-09-23). Vy Spine not previously covered. [Source](https://orthospinenews.com/2026/11/17/vy-spine-announces-fda-clearance-of-3d-printed-vysion-p-si-fusion-and-vystop-si-screw-systems/)

- **Spine J (Mount Sinai, online Nov 16) meta-analysis of 134 studies and 15,649 LLIF patients (2009-2026): transient anterior thigh pain 13.9%, hip flexor weakness 10.2%, sensory deficit 9.9%; persistent motor 1.0%, sensory 2.2%; 30-day mortality 0.4%; subsidence 5.7%; reoperation 3.6%; neurologic burden declined over time** — PMID 43039300, PROSPERO CRD420261368348. Random-intercept logistic pooling; persistent deficits required six months of mean follow-up. 95% prediction interval for any transient neurologic event 0.9% to 60.5%. Any transient neurologic event and persistent motor deficit declined over time (p<0.001); reoperation stable. Authors: expected rates in individual settings may differ substantially from pooled averages. Prior LLIF item (2026-10-20) was a cost study, not this. [Source](https://doi.org/10.1016/j.spinee.2026.11.007)

### Contribute to the Brief

Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from [Studio](https://next.doc.social/studio).

Not on doc social yet? [Contribute a lecture or join the network](https://next.doc.social/contribute) — doc social is a clinical education platform for clinicians, and this show is one part of it.

_Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source._
